University of Toronto researchers have discovered nine new genes used by bacteria to protect themselves against ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, ...

Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...